FDA Approval, FY 2013 & Q4 FY 2013 Outlook, and Stock Price Updates - Research Report on Bio-Reference Laboratories, Zimmer, Boston Scientific, Covance, and MAKO Surgical

NEW YORK, December 2, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Bio-Reference Laboratories Inc. (NASDAQ: BRLI), Zimmer Holdings, Inc. (NYSE: ZMH), Boston Scientific Corporation (NYSE: BSX), Covance Inc. (NYSE: CVD), and MAKO Surgical Corp. (NASDAQ: MAKO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Bio-Reference Laboratories Inc. Research Report  

On November 27, 2013, Bio-Reference Laboratories Inc. (BRLI) released revenues and EPS outlook for full-year FY 2013 and Q4 FY 2013. The Company stated that it expects patient volume to grow 15% YoY in Q4 FY 2013, besides anticipating revenues of c.$192.0 million, up  17.4% YoY, and EPS of c.$0.40 per share, up 13.0% YoY during the quarter. For full-year FY 2013, the Company anticipates earnings per share of c.$1.65, compared to that of $1.51 per share in full-year FY 2012. Further BRLI informed that it intends to release its Q4 FY 2013 and full-year FY 2013 earnings and host a year-end conference call for the same on December 19, 2013. According to BRLI, despite continued strong volume growth, there is an ongoing recalibration of reimbursement for the industry, which has resulted in substantial downward pressure from many payers regarding reimbursement in FY 2013. The Full Research Report on Bio-Reference Laboratories Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1f59_BRLI

--

Zimmer Holdings, Inc Research Report

On November 27, 2013, stock of Zimmer Holdings, Inc (Zimmer) rose 0.02% to $90.62 at the end of the trading session. Over the previous three trading sessions, Zimmer's shares gained 1.55%, as compared to the Dow Jones Industrial Average Index, which gained 0.20% during the same period. The Full Research Report on Zimmer Holdings, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/9db9_ZMH

--

Boston Scientific Corporation Research Report

On November 25, 2013, Boston Scientific Corporation (Boston Scientific) announced that the U.S. Food and Drug Administration (FDA), has approved its Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, its next-generation durable polymer drug-eluting stent (DES). According to Boston Scientific, the Promus PREMIER™ Stent System offers physicians improved DES performance in treating patients with coronary artery disease, and features unique customized platinum chromium alloy stent architecture, the market-leading Everolimus drug with a biocompatible, fluorinated co-polymer and an enhanced stent delivery system. "The Promus PREMIER Stent System reflects our commitment to DES technology and to providing interventional cardiologists with the most complete portfolio of clinical solutions," said Kevin Ballinger, President, Interventional Cardiology, Boston Scientific. "Through ongoing collaboration with physicians, we expect to continue to innovate and build on our industry-leading platinum chromium platform." The Company also stated that the technology will be immediately available in the U.S., with the first implantation scheduled to be performed by Martin Leon, M.D., Director, Center for Interventional Vascular Therapy at Columbia University Medical Center / New York-Presbyterian Hospital, New York City. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5640_BSX

--

Covance Inc. Research Report

On November 27, 2013, shares of Covance Inc. (Covance) rose 0.27% to $84.69 at the close of trading session. Shares of Covance rose 1.00% over the past three trading sessions, while the Dow Jones Industrial Average Index rose 0.20% during the same period. The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5691_CVD

--

MAKO Surgical Corp. Research Report

On November 27, 2013, MAKO Surgical Corp.'s (MAKO) stock ended the day's trading session at $29.96, up 0.07%. MAKO's stocks gained 0.10% over the past three trading sessions, while the NASDAQ composite Index gained 1.33% during the same period. The Full Research Report on MAKO Surgical Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7465_MAKO

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED